Wuxi Biologic to Acquire Bayer’s Production Facility in Germany

 Wuxi Biologic to Acquire Bayer’s Production Facility in Germany

Wuxi Biologic; Acquire; Bayer; Production Facility; Germany

Shots:

  • Wuxi Biologic to take over operations of Bayer’s manufacturing plants in Leverkusen, Germany and purchase its associated equipment in combination with a long-term lease contract for the building
  • As per the manufacturing agreement to be negotiated, Wuxi operated plant shall serve as a backup site for manufacturing Kovaltry, an antihemophilic factor (recombinant) while Bayer’s facility in California, US will remain the major site for manufacturing and filing of it
  • Kovaltry is used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in patients with hemophilia A and controls bleeding in hemophilic patients

Click here ­to­ read full press release/ article | Ref: Bayer | Image: The Pharma Letter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post